The Latest Breaking News from Teleflex

Despite Teleflex’s underperformance relative to the Dow Jones over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Although Teleflex has lagged behind the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Despite the prevailing bearish investor sentiment, the healthcare industry is expected to continue growing amid an increase in global chronic diseases, rapid medical advancements, and an aging population. The stocks of quality healthcare companies Bausch Health (BHC), Teleflex (TFX), Abcam (ABCM), and Integra LifeSciences (IART) are currently trading near their…

Upgrades

According to Benzinga Pro, during Q1, Teleflex (NYSE:TFX) earned $77.14 million, a 39.77% increase from the preceding quarter. Teleflex's sales decreased to $641.72 million, a 15.78% change since Q4.

RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance. 

Needham has decided to maintain its Buy rating of Teleflex (NYSE:TFX) and lower its price target from $400.00 to $355.00. Shares of Teleflex are trading down 1.62% over the last 24 hours, at $290.71 per share. A move to $355.00 would account for a 22.11% increase from the current share…

Over the past 3 months, 7 analysts have published their opinion on Teleflex (NYSE:TFX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

  Teleflex (NYSE:TFX) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:30 AM. Here's what investors need to know about the announcement.